141080 — LigaChem Biosciences Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapNeutral

Annual cashflow statement for LigaChem Biosciences, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-6,986	-23,391	-45,092	-73,704	7,800
Depreciation
Amortisation
Deferred Taxes
Non-Cash Items	-2,522	3,058	13,365	5,443	-14,194
Unusual Items
Purchased R&D
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-8,380	-24,765	20,475	1,353	79,862
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-14,893	-42,049	-7,136	-62,236	78,476
Capital Expenditures	-3,219	-18,603	-4,772	-2,202	-5,701
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	3,568	-25,341	-11,397	11,569	-451,673
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	349	-43,944	-16,169	9,367	-457,374
Financing Cash Flow Items	-157	-26.3	-2.64	-4.21	-61.6
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	2,633	171,292	3,199	-1,909	443,379
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-12,240	85,291	-21,975	-54,911	65,858